Product Information
PHENTERMINE 37.5 MG TABLET is a generic product labeled by Sunrise Pharmaceutical Inc., priced at $0.0727 per EA under NDC 11534016030. Its NADAC has been published 386 times since May 15, 2019.
FDA first approved this application on Sep 25, 2014. Its Orange Book therapeutic-equivalence code is AA.
Strength
37.5 mg/1
Manufacturer
Sunrise Pharmaceutical Inc.NDC
11534016030
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PHENTERMINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA205008FDA Approved
9/25/2014
TE Code
AA
On Market Since
1/24/2017
Pharmacological Classes
Price Statistics
The NADAC for PHENTERMINE 37.5 MG TABLET has been published 386 times since May 15, 2019, and over the history we have for it it has declined 20.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0727 per EA |
|---|---|
| All-time high | $0.1061 (Jul 10, 2019) |
| All-time low | $0.0494 (Nov 20, 2024) |
| 52-week high | $0.0727 |
| 52-week low | $0.0670 |
| Median price | $0.0805 |
| Average price | $0.0800 |
| Largest weekly change | +51.9% (Jun 19, 2024) |
| Weeks tracked | 386 |
| Tracking since | May 15, 2019 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sunrise Pharmaceutical Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
phentermine hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Sympathomimetic Amine Anorectic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PHENTERMINE 37.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for PHENTERMINE 37.5 MG TABLET, manufactured by Sunrise Pharmaceutical Inc., is $0.0727 per EA (NDC 11534016030), effective Sep 30, 2026.
How has the price of PHENTERMINE 37.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for PHENTERMINE 37.5 MG TABLET has declined 20.4%. It has been tracked across 386 weekly CMS publications since May 15, 2019.
What are the highest and lowest recorded NADAC prices for PHENTERMINE 37.5 MG TABLET?
Since May 15, 2019, the NADAC for PHENTERMINE 37.5 MG TABLET has ranged from a low of $0.0494 (Nov 20, 2024) to a high of $0.1061 (Jul 10, 2019), with a median of $0.0805 per EA.
Are there cheaper alternatives to PHENTERMINE 37.5 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as PHENTERMINE 37.5 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures PHENTERMINE 37.5 MG TABLET?
PHENTERMINE 37.5 MG TABLET (NDC 11534016030) is labeled by Sunrise Pharmaceutical Inc., and CMS classifies it as a generic product.